|
|
腹水细胞学在早期辅助诊断卵巢恶性肿瘤性质中的意义
|
Abstract:
目的：对腹水中的有形细胞学成分进行切片检查，分析其各类标志物的异常变化对卵巢癌细胞生物学行为及治疗效果的影响进行综述，对早期明确卵巢恶性肿瘤的性质及选取更加个性化的治疗方案提供参考。方法：检索PubMed、Medline、Cochrane图书馆、中国知网(CNKI)、维普(VIP)、万方数据发表的关于检测腹水细胞学标志物对卵巢恶性肿瘤生物学行为及治疗预后的影响的相关文献并对其进行综述分析。结果：共搜集到33篇关于腹水及实体肿瘤组织中的不同表达情况的中英文文献，多项国内外研究表明，对卵巢癌患者行腹水细胞学检查对明确肿瘤细胞的生物学行为及指导治疗预后存在指导意义。结论：腹水细胞学标志物的异常变化对卵巢癌的组织学类型及分期分化、转移侵袭能力、治疗及耐药性、生存及预后均有影响。
Objective: To perform section examination of tangible cytological components in ascitic fluid and analyze the impact of abnormal changes in each type of their markers on the biological behavior and therapeutic effects of ovarian cancer cells, to provide references on the nature of early defini-tive ovarian malignancies and on the selection of more personalized treatment options. Methods: Relevant literatures published by PubMed, MEDLINE, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP, Wan fang Data on detecting the influence of cytological markers of asci-tes on biological behavior and treatment outcomes of ovarian malignancies were reviewed and an-alyzed. Results: A total of 33 articles in Chinese and English regarding ascites and different expres-sion profiles in solid tumor tissues were retrieved, and several studies at home and abroad indi-cated that cytological examination of ascites fluid in patients with ovarian cancer is instructive in defining the biological behavior of tumor cells and guiding the prognosis of treatment. Conclusions: Abnormal changes in cytological markers of ascites have been shown to influence the histological type and stage differentiation, metastatic invasive ability, treatment and drug resistance, survival and prognosis of ovarian cancer.
| [1] | Freddie, B., Jacques, F., Isabelle, S., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492 |
| [2] | Meyer, L.A., He, W.G., Sun, C.C., et al. (2018) Neoadjuvant Chemother-apy in Elderly Women with Ovarian Cancer: Rates of Use and Effectiveness. Gynecologic Oncology, 150, 451-459. https://doi.org/10.1016/j.ygyno.2018.06.020 |
| [3] | 万佳红, 唐晓旭. 血清及腹水肿瘤标志物诊断良恶性腹水的临床研究[J]. 国际检验医学杂志, 2017, 38(20): 2811-2812, 2815. |
| [4] | 孙晨希, 刘贵生, 付佐君. CDX2/PAX8/CA125在不明来源癌性腹水诊断中的研究进展[J]. 中国临床研究, 2021, 34(4): 538-541. |
| [5] | Shender, V.O., Pavlyukov, M.S., Ziganshin, R.H., et al. (2014) Proteome-Metabolome Profiling of Ovarian Cancer Ascites Reveals Novel Components Involved in Intercellular Communication. Molecular & Cellular Proteomics: MCP, 13, 3558-3571. https://doi.org/10.1074/mcp.M114.041194 |
| [6] | 卢淮武, 吴斌, 许妙纯, 等. 《2022 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2022, 38(3): 310-318. |
| [7] | 宋玉霞, 赵涛, 王宏卫, 等. 卵巢癌腹水中不同肿瘤相关性巨噬细胞亚型IL-10、IL-12表达的差异[J]. 河北医科大学学报, 2017, 38(6): 676-679. |
| [8] | 李晓峰, 张锐, 李金玲. 卵巢癌患者腹水和外周血中CA125和CD4~+CD25~+调节性T细胞含量监测的临床价值[J]. 中国妇幼保健, 2021, 36(14): 3199-3200. |
| [9] | Capellero, S., Erriquez, J., Battistini, C., et al. (2022) Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells. International Journal of Molecular Sciences, 23, 833. https://doi.org/10.3390/ijms23020833 |
| [10] | Bansal, A., Srinivasan, R., Rohilla, M., et al. (2020) Morphologic and Immunocytochemical Features of High-Grade Serous Carci-noma of Ovary in Ascitic Fluid Effusion and Fine-Needle Aspiration Cytology. American Journal of Clinical Pathology, 154, 103-114. https://doi.org/10.1093/ajcp/aqaa028 |
| [11] | Mo, L.H., Bachelder, R.E., Kennedy, M., et al. (2015) Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78. Molecular Cancer Therapeutics, 14, 747- 756. https://doi.org/10.1158/1535-7163.MCT-14-0579 |
| [12] | Huang, H., Li, Y.J., Lan, C.Y., et al. (2013) Clinical Sig-nificance of Ascites in Epithelial Ovarian Cancer. Neoplasma, 60, 546-552. https://doi.org/10.4149/neo_2013_071 |
| [13] | Ford, C.E., Werner, B., Hacker, N.F., et al. (2020) The Untapped Po-tential of Ascites in Ovarian Cancer Research and Treatment. British Journal of Cancer, 123, 9-16. https://doi.org/10.1038/s41416-020-0875-x |
| [14] | Ahmed, N. and Stenvers, K.L. (2013) Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy- Based Translational Research. Frontiers in Oncology, 3, 256. https://doi.org/10.3389/fonc.2013.00256 |
| [15] | Lane, D., Matte, I., Laplante, C., et al. (2016) CCL18 from Ascites Promotes Ovarian Cancer Cell Migration through Proline-Rich Tyrosine Kinase 2 Signaling. Molecular Cancer, 15, 58. https://doi.org/10.1186/s12943-016-0542-2 |
| [16] | Siddiqui, I., Erreni, M., Kamal, M.A., et al. (2017) Differential Role of Interleukin-1 and Interleukin-6 in K-Ras-Driven Pancreatic Carcinoma Undergoing Mesenchymal Transition. Oncoimmunology, 17, e1388485.
https://doi.org/10.1080/2162402X.2017.1388485 |
| [17] | Dalal, V., Kumar, R., Kumar, S., et al. (2018) Biomarker Potential of IL-6 and VEGF-A in Ascitic Fluid of Epithelial Ovarian Cancer Patients. Clinica Chimica Acta; International Journal of Clinical Chemistry, 482, 27-32.
https://doi.org/10.1016/j.cca.2018.03.019 |
| [18] | Szender, J.B., Emmons, T., Belliotti, S., et al. (2017) Impact of As-cites Volume on Clinical Outcomes in Ovarian Cancer: A Cohort Study. Gynecologic Oncology, 146, 491-497. https://doi.org/10.1016/j.ygyno.2017.06.008 |
| [19] | 刘萍. 卵巢癌腹水与卵巢癌耐药的相关性研究[D]: [硕士学位论文]. 天津: 天津医科大学, 2016. |
| [20] | Szulc-Kielbik, I., Kielbik, M., Nowak, M., et al. (2021) The Implication of IL-6 in the Invasiveness and Chemoresistance of Ovarian Cancer Cells. Systematic Review of Its Potential Role as a Bi-omarker in Ovarian Cancer Patients. Biochimica et Biophysica Acta, 1876, Article ID: 188639. https://doi.org/10.1016/j.bbcan.2021.188639 |
| [21] | 李庆. 卵巢癌腹水形成的分子机制及治疗进展[J]. 系统医学, 2019, 4(22): 192-195. |
| [22] | Monavarian, M., Elhaw, A.T., Tang, P.W., et al. (2022) Emerging Perspectives on Growth Factor Metabolic Relationships in the Ovarian Cancer Ascites Environment. Seminars in Cancer Biology, 86, 709-719.
https://doi.org/10.1016/j.semcancer.2022.03.004 |
| [23] | Zhang, S.B., Xie, B.F., Wang, L.J., et al. (2021) Macro-phage-Mediated Vascular Permeability via VLA4/VCAM1 Pathway Dictates Ascites Development in Ovarian Cancer. The Journal of Clinical Investigation, 131, e140315.
https://doi.org/10.1172/JCI140315 |
| [24] | Lane, D., Matte, I., Garde-Granger, P., et al. (2015) Inflamma-tion-Regulating Factors in Ascites as Predictive Biomarkers of Drug Resistance and Progression-Free Survival in Serous Epithelial Ovarian Cancers. BMC Cancer, 15, Article No. 492. https://doi.org/10.1186/s12885-015-1511-7 |
| [25] | Jie, X.X., Du, M., Zhang, M., et al. (2022) Mutation Analysis of Circulating Tumor DNA and Paired Ascites and Tumor Tissues in Ovarian Cancer. Experimental and Therapeutic Medicine, 24, 542.
https://doi.org/10.3892/etm.2022.11479 |
| [26] | Trachana, S.P., Pilalis, E., Gavalas, N.G., et al. (2016) The Develop-ment of an Angiogenic Protein “Signature” in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling. PLOS ONE, 11, e0156403.
https://doi.org/10.1371/journal.pone.0156403 |
| [27] | Fumagalli, C., Rappa, A., Casadio, C., et al. (2019) Next-Generation Sequencing-Based BRCA Testing on Cytological Specimens from Ovarian Cancer Ascites Reveals high Concordance with Tumour Tissue Analysis. Journal of Clinical Pathology, 73, 168-171. https://doi.org/10.1136/jclinpath-2019-206127 |
| [28] | Kolomeyevskaya, N., Eng, K.H., Khan, A.N.H., et al. (2015) Cytokine Profiling of Ascites at Primary Surgery Identifies an Interaction of Tumor Necrosis Factor-α and Interleukin-6 in Predicting Reduced Progression-Free Survival in Epithelial Ovarian Cancer. Gynecologic Oncology, 138, 352-357. https://doi.org/10.1016/j.ygyno.2015.05.009 |
| [29] | Carroll, M.J., Kaipio, K., Hynninen, J., et al. (2022) A Subset of Secreted Proteins in Ascites Can Predict Platinum- Free Interval in Ovarian Cancer. Cancers, 14, 4291. https://doi.org/10.3390/cancers14174291 |
| [30] | Coosemans, A.N., Baert, T., D’heygere, V., et al. (2019) Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer. Anticancer Research, 39, 5953-5962.
https://doi.org/10.21873/anticanres.13800 |
| [31] | Kipps, E., Tan, D.S.P. and Kaye, S.B. (2013) Meeting the Challenge of Ascites in Ovarian Cancer: New Avenues for Therapy and Research. Nature Reviews. Cancer, 13, 273-282. https://doi.org/10.1038/nrc3432 |
| [32] | 黄于峰. 腹水及血清CA125动力学对高级别浆液性卵巢癌化疗敏感性及预后的相关性分析[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2021. |
| [33] | Almeida-Nunes, D.L., Mendes-Frias, A., Silvestre, R., et al. (2022) Immune Tumor Microenvironment in Ovarian Cancer Ascites. International Journal of Molecular Sciences, 23, Article 10692.
https://doi.org/10.3390/ijms231810692 |
